Even though the global pattern of enriched genes in carcinoma tissues and normal tissues showed variability between patients, it was possible to identify differentially H3K27me3-enriched genes involved in prostate cancer based on enrichment score level. Using ANOVA, we identified genes that were significantly enriched between both tumor groups versus normal samples. The significance of the enrichment score values of ALG5, EXOSC8, CBX1, GRID2, GRIN3B, ING3, MYO1D, NPHP3-AS1, MSH6, FBXO11, SND1, SPATS2, TENM4 and TRA2A genes are shown in Table 2. Association of H3K27me3 enrichment and clinico-pathological variables like stage and PSA level did not show any significance. However, only Gleason score correlated with the H3K27me3 enrichment on genes (Fig. 5).Table 2Compiled statistics of FDA and ANOVA resultsGene nameCoordinate axis 1Coordinate axis 2 p valueSignificance ALG5/EXOSC8 0.815−0.1540.001** CBX1 0.6430.0790.038* GRID2 0.6550.0560.034* GRIN3B 0.627−0.1680.039* ING3 0.0740.7480.020* MYO1D 0.666−0.1680.023* NPHP3-AS1 0.640−0.1860.031* MSH6/FBXO11 0.3660.5610.047* SND1 0.1870.6530.049* SPATS2 0.579−0.3520.031* TENM4 0.5920.3200.032* TRA2A 0.563−0.4120.025*Coordinate axes refer to FDA data values (Fig. 4). P value refers to ANOVA data. *<0.05 **< 0.01Differentially H3K27me3-enriched genes in prostate cancer tissues compared to normal biopsies Fig. 5Factorial discriminant analysis. The results represent differentially H3K27me3-enriched genes between prostate cancer tissues versus normal tissues. The Highly enrichment correlated with GS > 7